• 1
    Emond JC, Freeman RB Jr, Renz JF, Yersiz H, Rogiers X, Busuttil RW. Optimizing the use of donated cadaver livers: Analysis and policy development to increase the application of split-liver transplantation. Liver Transpl 2002; 8: 863872.
  • 2
    Hoofnagle JH, Lombardero M, Zetterman RK et al.. Donor age and outcome of liver transplantation. Hepatology 1996; 24: 8996.
  • 3
    Rustgi SD, Marino G, Halpern MT, Umana WO, Tolleris C, Rustgi VK. Impact of donor age on graft survival among liver transplant recipients: analysis of the United Network for Organ Sharing database. Transplant Proc 2002; 34: 32953297.
  • 4
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 5
    Rakela J, Vargas HE. Hepatitis C. Magnitude of the problem. Liver Transpl 2002; 8 (10. Suppl 1): S3S6.
  • 6
    Testa G, Crippin JS, Netto GJ et al.. Liver transplantation for hepatitis C. Recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553561.
  • 7
    Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248252.
  • 8
    Berenguer M, Prieto M, San Juan F et al.. Contribution of donor age to the recent decrease in patient survival among HCV infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 9
    Charlton M, Seaberg E, Wiesner R et al.. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823830.
  • 10
    Berenguer M, Crippin J, Gish R et al.. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 3441.
  • 11
    Burak KW, Kremers WK, Batts KP et al.. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362369.
  • 12
    Berenguer M, Ferrell L, Watson J et al.. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673684.
  • 13
    Charlton M. The impact of advancing donor age on histologic recurrence of hepatitis C infection: The perils of ignored maternal advice. Liver Transpl 2003; 9: 535537.
  • 14
    Inui T, Shinomiya N, Fukasawa M et al.. Growth-related signaling regulates activation of telomerase in regenerating hepatocytes. Exp Cell Res 2002; 273: 147156.
  • 15
    Feray C, Caccamo L, Alexander GJM et al.. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117: 619625.
  • 16
    Rosen HR, Shackleton CR, Higa L et al.. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 14531457.
  • 17
    Ghobrial RM, Farmer DG, Baquerizo A et al.. Orthotopic liver transplantation for hepatitis C. outcome, effect of immunosuppression, and causes of retransplantation during an 8 year single center experience. Ann Surg 1999; 229: 824833.
  • 18
    Hunt J, Gordon FD, Lewis WD et al.. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens. Liver Transpl 2001; 7: 10561063.
  • 19
    Ghobrial RM, Gornbein J, Steadman R et al.. Pretransplant model to predict postransplant survival in liver transplant recipients. Ann Surg 2002; 236: 315322.
  • 20
    Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493499.
  • 21
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C. Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5 (4 Suppl 1): S107S114.
  • 22
    Berenguer M, Prieto M, Cordoba J et al.. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection. J Hepatol 1998; 28: 756763.
  • 23
    Wiesner R, Rabkin J, Klintmalm G et al.. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442450.
  • 24
    Jain A, Kashyap R, Demetris AJ, Eghst esa B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 4046.
  • 25
    Nelson DR, Soldevila-Pico C, Reed A et al.. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 10641070.
  • 26
    Zhou S, Terrault NA, Ferrell L et al.. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia. Hepatology 1996; 24: 10411046.
  • 27
    Mazzaferro V, Regalia E, Doci R et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693699.